Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription 10.06.2024 1 AJR Am J Roentgenol 1 Am J Surg 2 Ann Oncol 5 Ann Surg Oncol 11 Anticancer Res 2 BMC Cancer 1 Br J Cancer 1 Breast Cancer 1 Breast Cancer (Auckl) 2 Breast Cancer (Dove Med Press) 7 Breast Cancer Res 5 Breast Cancer Res Treat 1 Cancer 2 Cancer Cell 2 Cancer Epidemiol Biomarkers Prev 3 Cancer Res 4 Clin Breast Cancer 3 Clin Cancer Res 1 Eur J Surg Oncol 2 Histopathology 5 J Clin Oncol 2 J Natl Cancer Inst 5 J Surg Oncol 1 N Engl J Med 3 NPJ Breast Cancer 2 Oncol Rep 1 Oncology 1 PLoS Comput Biol 1 PLoS Genet 2 PLoS One 1 Radiol Imaging Cancer 2 Radiology 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. THOMAS M
   Editorial Comment: Abbreviated Breast MRI on Repeat-Is This a New Era for Breast Cancer Screening?
   AJR Am J Roentgenol. 2024 Jun 5. doi: 10.2214/AJR.24.31513.
   PubMed        
   
   

   
   Am J Surg

2. PESAVENTO CM, Kazemi RJ, Kappelman A, Thompson JL, et al
   Pilot testing a patient decision aid as a strategy to reduce overtreatment for older women with early-stage breast cancer.
   Am J Surg. 2024 May 25:115774. doi: 10.1016/j.amjsurg.2024.115774.
   PubMed         Abstract available
   
   

   
   Ann Oncol

3. ORLANDI A, Mastrantoni L, Bria E, Tortora G, et al
   To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall
   Ann Oncol. 2024 Jun 3:S0923-7534(24)00719-1. doi: 10.1016/j.annonc.2024.
   PubMed        
   
   
4. SHERRY AD, Lin TA, McCaw ZR, Ludmir EB, et al
   Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M.
   Ann Oncol. 2024 Jun 3:S0923-7534(24)00718-X. doi: 10.1016/j.annonc.2024.
   PubMed        
   
   

   
   Ann Surg Oncol

5. BHIMANI F, Feldman S, Cavalli A, Chen Y, et al
   Axillary Reverse Mapping Aids in Reducing the Rates of Breast Cancer-Related Lymphedema in Underserved Ethnically Diverse Population.
   Ann Surg Oncol. 2024 Jun 6. doi: 10.1245/s10434-024-15577.
   PubMed         Abstract available
   
   
6. JUNG JJ, Cheun JH, Kang E, Shin I, et al
   ASO Visual Abstract: Survival After the Contralateral Axillary Metastasis in Breast Cancer.
   Ann Surg Oncol. 2024 Jun 6. doi: 10.1245/s10434-024-15546.
   PubMed        
   
   
7. GILMORE RC, Fine RE
   Reply to: Comment on: Cryoablation Without Excision for Low-Risk Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial.
   Ann Surg Oncol. 2024 Jun 5. doi: 10.1245/s10434-024-15502.
   PubMed        
   
   
8. MYERS SP, Sevilimedu V, Jones VM, Abuhadra N, et al
   ASO Visual Abstract: Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple-Negative Breast Cancer.
   Ann Surg Oncol. 2024 Jun 4. doi: 10.1245/s10434-024-15491.
   PubMed        
   
   
9. KRECKO LK, Neuman HB, Greenberg CC, Wilke LG, et al
   Validation of the AJCC 8th Edition Breast Cancer Prognostic Staging System in Legacy Alliance Trials (AFT-01).
   Ann Surg Oncol. 2024 Jun 2. doi: 10.1245/s10434-024-15477.
   PubMed         Abstract available
   
   

   
   Anticancer Res

10. OMORI S, Ijichi H, Wakasugi A, Shigechi T, et al
    Association Between Preoperative Osteopenia and Prognosis in Breast Cancer Patients.
    Anticancer Res. 2024;44:2671-2679.
    PubMed         Abstract available
    
    
11. RADES D, Janssen S, Narvaez-Wolf CA, Kristiansen C, et al
    Seasonal Impact on Grade >/=2 Dermatitis in Patients With Breast Cancer Undergoing Radiotherapy: A Supplementary Analysis.
    Anticancer Res. 2024;44:2617-2620.
    PubMed         Abstract available
    
    
12. SUWANNALERT P, Panpinyaporn P, Wantanachaisaeng P, Teeppaibul T, et al
    A Potential Combination of Targeting HSP90 and mTOR in Breast Cancer Cell Growth, Migration, and Invasion Through Inhibiting AKT Phosphorylation and F-actin Organization.
    Anticancer Res. 2024;44:2555-2565.
    PubMed         Abstract available
    
    
13. SUGAWARA-KOMATSU K, Fujii T, Kurozumi S, Ishikawa H, et al
    Significance of MUC1 and beta-Catenin Localization in Mucinous Carcinoma of the Breast.
    Anticancer Res. 2024;44:2689-2698.
    PubMed         Abstract available
    
    
14. MOKBEL K, Mokbel K
    Harnessing Micronutrient Power: Vitamins, Antioxidants and Probiotics in Breast Cancer Prevention.
    Anticancer Res. 2024;44:2287-2295.
    PubMed         Abstract available
    
    
15. GUNNELLINI M, Tornincasa A, Montedoro M, Caprodossi A, et al
    Neoadjuvant Treatment for a cT4cN+ HER2+ Breast Cancer: Case Report of a Therapeutic Success.
    Anticancer Res. 2024;44:2755-2758.
    PubMed         Abstract available
    
    
16. PIOQUINTO-AVILA E, Gonzalez-Cruz AO, Solis-Estrada J, Hernandez-Juarez J, et al
    Anticancer Activity of HER2-targeting CPP-PTEN-THP Chimeric Proteins.
    Anticancer Res. 2024;44:2567-2575.
    PubMed         Abstract available
    
    
17. CHANG CM, Pekkle Lam HY
    Intratumoral Microbiota: Unraveling their Oncogenic Impact on Cancer Progression With Focus on Breast Cancer Therapeutic Outcomes.
    Anticancer Res. 2024;44:2271-2285.
    PubMed         Abstract available
    
    
18. WOO SH, Jung BC, Kim JY, Lee YH, et al
    Pulsed Electromagnetic Field Enhances Caffeic Acid Phenethyl Ester-induced Death of MCF-7 Breast Cancer Cells.
    Anticancer Res. 2024;44:2407-2415.
    PubMed         Abstract available
    
    
19. CHU J, DO SI, Kim HS
    Age-related Differences in Spatially Resolved Transcriptomic Profiles of Patients With Hormone Receptor-positive Breast Carcinoma.
    Anticancer Res. 2024;44:2605-2616.
    PubMed         Abstract available
    
    
20. AGHIMIEN MO, Kolawole Q, Igbinoba PO, Musa MA, et al
    Non-cytotoxic 3-Acetylcoumarin as an Attractive Target for Human Monoamine Oxidase (HMAO) Enzymes.
    Anticancer Res. 2024;44:2335-2341.
    PubMed         Abstract available
    
    

    
    BMC Cancer

21. XU JX, Zhu QL, Bi YM, Peng YC, et al
    New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis.
    BMC Cancer. 2024;24:691.
    PubMed         Abstract available
    
    
22. YE J, Ying J, Chen H, Wu Z, et al
    PPIH acts as a potential predictive biomarker for patients with common solid tumors.
    BMC Cancer. 2024;24:681.
    PubMed         Abstract available
    
    

    
    Br J Cancer

23. RYU H, Shin KH, Chang JH, Jang BS, et al
    A nationwide study of breast reconstruction after mastectomy in patients with breast cancer receiving postmastectomy radiotherapy: comparison of complications according to radiotherapy fractionation and reconstruction procedures.
    Br J Cancer. 2024 Jun 5. doi: 10.1038/s41416-024-02741.
    PubMed         Abstract available
    
    

    
    Breast Cancer

24. CHEN Y, Zhou Y, Chen J, Yang J, et al
    Exosomal lncRNA SNHG12 promotes angiogenesis and breast cancer progression.
    Breast Cancer. 2024 Jun 4. doi: 10.1007/s12282-024-01574.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

25. YU M, Liu Y, Huang Z, Zhu Q, et al
    The Feasibility and Reliability of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients With Negative Axillary Lymph Nodes-A Meta-analysis.
    Breast Cancer (Auckl). 2024;18:11782234241255856.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

26. FENTAW S, Godana AA, Abathun D, Chekole DM, et al
    Comparative Analysis of Women's Breast Cancer Survival Time at Three Selected Government Referral Hospitals in Ethiopia's Amhara Region Using Parametric Shared Frailty Models.
    Breast Cancer (Dove Med Press). 2024;16:269-287.
    PubMed         Abstract available
    
    
27. GUO L, Hong SC, Wang X, Wang SQ, et al
    Modulatory Effects of XIAOPI Formula on CXCL1 and Selected Outcomes in Triple-Negative Breast Cancer: A Randomized Controlled Clinical Trial.
    Breast Cancer (Dove Med Press). 2024;16:289-303.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

28. MORLA-BARCELO PM, Laguna-Macarrilla D, Cordoba O, Matheu G, et al
    Unraveling malignant phenotype of peritumoral tissue: transcriptomic insights into early-stage breast cancer.
    Breast Cancer Res. 2024;26:89.
    PubMed         Abstract available
    
    
29. BOISSIN C, Wang Y, Sharma A, Weitz P, et al
    Deep learning-based risk stratification of preoperative breast biopsies using digital whole slide images.
    Breast Cancer Res. 2024;26:90.
    PubMed         Abstract available
    
    
30. JOHN EM, Koo J, Phipps AI, Longacre TA, et al
    Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.
    Breast Cancer Res. 2024;26:88.
    PubMed         Abstract available
    
    
31. FARALDO MM, Romagnoli M, Wallon L, Dubus P, et al
    Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion.
    Breast Cancer Res. 2024;26:91.
    PubMed         Abstract available
    
    
32. JIN X, Yang S, Lu X, Chen X, et al
    Increased expression of REG3A promotes tumorigenic behavior in triple negative breast cancer cells.
    Breast Cancer Res. 2024;26:92.
    PubMed         Abstract available
    
    
33. DUIVON M, Lequesne J, Di Meglio A, Pradon C, et al
    Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study.
    Breast Cancer Res. 2024;26:93.
    PubMed         Abstract available
    
    
34. ZHANG X, An K, Ge X, Sun Y, et al
    NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m(5)C methylation.
    Breast Cancer Res. 2024;26:94.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

35. YIN C, Li H, Zhang B, Liu Y, et al
    Expression of Concern to: RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition.
    Breast Cancer Res Treat. 2024 Jun 6. doi: 10.1007/s10549-024-07392.
    PubMed        
    
    
36. FRANCOIS C, Mailliez A, Chretien S, Leguillette C, et al
    Therapeutic impact of (18)F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer.
    Breast Cancer Res Treat. 2024 Jun 5. doi: 10.1007/s10549-024-07386.
    PubMed         Abstract available
    
    
37. SCOTT OW, TinTin S, Cavadino A, Elwood JM, et al
    Beta-blocker use and breast cancer outcomes: a meta-analysis.
    Breast Cancer Res Treat. 2024 Jun 5. doi: 10.1007/s10549-024-07263.
    PubMed         Abstract available
    
    
38. ELSON NC, Wernke K, Yoder LM, Fellner AN, et al
    Universal genetic counseling in breast cancer patients significantly improves overall testing rates and improves completion rates in subpopulations.
    Breast Cancer Res Treat. 2024 Jun 1. doi: 10.1007/s10549-024-07329.
    PubMed         Abstract available
    
    
39. SHI W, Xu C, Lei P, Sun X, et al
    A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets for breast cancer.
    Breast Cancer Res Treat. 2024 Jun 4. doi: 10.1007/s10549-024-07373.
    PubMed         Abstract available
    
    

    
    Cancer

40. SELMOUNI F, Bendahhou K, Sauvaget C, Abahssain H, et al
    Impact of CBE-based screening program on care pathway, stage at diagnosis, nature of treatment, and overall survival among breast cancer patients in Morocco.
    Cancer. 2024 Jun 4. doi: 10.1002/cncr.35419.
    PubMed         Abstract available
    
    

    
    Cancer Cell

41. MCGINNIS CS, Miao Z, Superville D, Yao W, et al
    The temporal progression of lung immune remodeling during breast cancer metastasis.
    Cancer Cell. 2024 May 24:S1535-6108(24)00167-3. doi: 10.1016/j.ccell.2024.
    PubMed         Abstract available
    
    
42. LAYER N, Bunse L, Venkataramani V
    Neural deception: Breast cancer co-opts neuronal mechanisms to evade the immune system.
    Cancer Cell. 2024 May 17:S1535-6108(24)00170-3. doi: 10.1016/j.ccell.2024.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

43. YAGHJYAN L, Wang Z, Warner ET, Rosner B, et al
    Reproductive Factors Related to Childbearing and a Novel Automated Mammographic Measure, V.
    Cancer Epidemiol Biomarkers Prev. 2024;33:804-811.
    PubMed         Abstract available
    
    
44. LOHANI KR, Nibbe AM, Vierkant RA, Pacheco-Spann LM, et al
    Understanding benign breast disease and subsequent breast cancer in Hispanic white females; a step closer to evidence-based management.
    Cancer Epidemiol Biomarkers Prev. 2024 Jun 5. doi: 10.1158/1055-9965.EPI-24-0204
    PubMed         Abstract available
    
    

    
    Cancer Res

45. ELEMENTO O
    How Artificial Intelligence Unravels the Complex Web of Cancer Drug Response.
    Cancer Res. 2024;84:1745-1746.
    PubMed         Abstract available
    
    
46. SUN X, Verma SP, Jia G, Wang X, et al
    Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants that Confer Risk for Breast Cancer.
    Cancer Res. 2024 Jun 4. doi: 10.1158/0008-5472.CAN-23-3854.
    PubMed         Abstract available
    
    
47. TUCKER JB, Carlsen CL, Scribano CM, Pattaswamy SM, et al
    CENP-E inhibition induces chromosomal instability and synergizes with diverse microtubule-targeting agents in breast cancer.
    Cancer Res. 2024 Jun 4. doi: 10.1158/0008-5472.CAN-23-3332.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

48. YANG FA, Wu PJ, Su YT, Strong PC, et al
    Effect of Kinesiology Taping on Breast Cancer-Related Lymphedema: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Clin Breast Cancer. 2024 May 1:S1526-8209(24)00113.
    PubMed         Abstract available
    
    
49. LI N, Xiao C, Li Y, Zhang Y, et al
    Association of Chlamydia trachomatis Infection With Breast Cancer Risk and the Modification Effect of IL-12.
    Clin Breast Cancer. 2024 May 10:S1526-8209(24)00116.
    PubMed         Abstract available
    
    
50. DALY GR, Dowling GP, Hamza E, AlRawashdeh M, et al
    Does Sentinel Lymph Node Biopsy Influence Subsequent Management Decisions in Women With Breast Cancer >/= 70 Years Old?
    Clin Breast Cancer. 2024 May 7:S1526-8209(24)00115.
    PubMed         Abstract available
    
    
51. LIU M, Xiang Q, Dai F, Yuan Y, et al
    Comparison of the Pathological Complete Response Rate and Survival Between HER2-Low and HER2-Zero Breast Cancer in Neoadjuvant Chemotherapy Setting: A Systematic Review and Meta-Analysis.
    Clin Breast Cancer. 2024 May 10:S1526-8209(24)00114.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

52. JANK P, Karn T, van Mackelenbergh M, Lindner J, et al
    An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-24-0459.
    PubMed         Abstract available
    
    
53. ZHANG Q, Cai Z, Gerratana L, Davis AA, et al
    Early evaluation of risk stratification and clinical outcomes for patients with advanced breast cancer through combined monitoring of baseline circulating tumor cells and DNA.
    Clin Cancer Res. 2024 Jun 3. doi: 10.1158/1078-0432.CCR-24-0535.
    PubMed         Abstract available
    
    
54. MAKHLIN I, Demissei BG, D'Agostino R, Hundley WG, et al
    Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial.
    Clin Cancer Res. 2024;30:2370-2376.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

55. YEO HAO XUAN M, Masuda Y
    Reply to: Surgery vs. non-surgery for liver metastases from primary breast cancer.
    Eur J Surg Oncol. 2024 May 29:108446. doi: 10.1016/j.ejso.2024.108446.
    PubMed        
    
    

    
    Histopathology

56. LAOKULRATH N, Gudi M, Salahuddin SA, Chong APY, et al
    Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges.
    Histopathology. 2024 Jun 6. doi: 10.1111/his.15213.
    PubMed         Abstract available
    
    
57. MILIGY IM, Awasthi R, Mir Y, Khurana A, et al
    Morphological and molecular changes of oestrogen receptor-positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study.
    Histopathology. 2024 Jun 7. doi: 10.1111/his.15238.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

58. SOLDATO D, Michiels S, Havas J, Di Meglio A, et al
    Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer.
    J Clin Oncol. 2024 Jun 5:JCO2301959. doi: 10.1200/JCO.23.01959.
    PubMed         Abstract available
    
    
59. CHAVEZ-MACGREGOR M, Miao J, Pusztai L, Goetz MP, et al
    Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy +/- 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.
    J Clin Oncol. 2024 Jun 4:JCO2302344. doi: 10.1200/JCO.23.02344.
    PubMed         Abstract available
    
    
60. BOSTANY G, Chen Y, Francisco L, Dai C, et al
    Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors.
    J Clin Oncol. 2024 Jun 4:JCO2301779. doi: 10.1200/JCO.23.01779.
    PubMed         Abstract available
    
    
61. SCHNEIDER BP, Zhao F, Ballinger TJ, Garcia SF, et al
    ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
    J Clin Oncol. 2024 Jun 3:JCO2400526. doi: 10.1200/JCO.24.00526.
    PubMed         Abstract available
    
    
62. CHAPMAN JW, Bayani J, SenGupta S, Bartlett JMS, et al
    Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.
    J Clin Oncol. 2024 Jun 2:JCO2400835. doi: 10.1200/JCO.24.00835.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

63. LIN J, Ouyang Y, Li Y, Jin L, et al
    Different dosage forms of GnRHa with endocrine therapy in premenopausal hormone Receptor-Positive breast cancer.
    J Natl Cancer Inst. 2024 Jun 4:djae115. doi: 10.1093.
    PubMed         Abstract available
    
    
64. CHUA AV JR, Sheng H, Liang E, Gandhi S, et al
    Epidemiology of early vs. Late recurrence among women with Early-Stage estrogen Receptor-Positive breast cancer in the pathways study.
    J Natl Cancer Inst. 2024 Jun 6:djae128. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

65. SALGADO MRT, Sobral DV, Martins MR, Salgado EFMT, et al
    Expression of CD28, FAS, PD1, and CTLA4 molecules in the blood of women with triple-negative breast cancer.
    J Surg Oncol. 2024 Jun 6. doi: 10.1002/jso.27725.
    PubMed         Abstract available
    
    
66. SOBRAL DV, Salgado MRT, Martins MR, Vasconcelos CS, et al
    Prognostic role of SOX2 and STAT3 expression on circulating T lymphocytes and CD44+/CD24(neg) cells in the locally advanced and metastatic breast cancer.
    J Surg Oncol. 2024 Jun 2. doi: 10.1002/jso.27716.
    PubMed         Abstract available
    
    
67. CHEN JC, Handley D, Elsaid MI, Fisher JL, et al
    Racial disparities in disease-specific mortality and surgical management of patients with ductal carcinoma in situ with microinvasion.
    J Surg Oncol. 2024;129:1179-1186.
    PubMed         Abstract available
    
    
68. KIM M, Vingan P, Boe LA, Tadros AB, et al
    Nonresponse data in sexual well-being among breast reconstruction patients-who are we overlooking?
    J Surg Oncol. 2024;129:1192-1201.
    PubMed         Abstract available
    
    
69. AMBIKA M, Lara S, Faulkner HR, Toncred S, et al
    Oncoplastic reconstruction with breast-conserving treatment versus breast-conserving treatment alone in the elderly.
    J Surg Oncol. 2024;129:1187-1191.
    PubMed         Abstract available
    
    

    
    N Engl J Med

70. VIDULA N, Rodriguez K, Wong AK, Boyraz B, et al
    Case 17-2024: A 45-Year-Old Woman with Metastatic Breast Cancer.
    N Engl J Med. 2024;390:2011-2022.
    PubMed        
    
    

    
    NPJ Breast Cancer

71. MAI N, Myers S, Shen S, Downs-Canner S, et al
    Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer.
    NPJ Breast Cancer. 2024;10:39.
    PubMed         Abstract available
    
    
72. ROSSETTI S, Broege A, Sen A, Khan S, et al
    Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models.
    NPJ Breast Cancer. 2024;10:40.
    PubMed         Abstract available
    
    
73. RUGO HS, Tolaney SM, Loirat D, Punie K, et al
    Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
    NPJ Breast Cancer. 2024;10:41.
    PubMed        
    
    

    
    Oncol Rep

74. ANWAR S, Zafar M, Hussain MA, Iqbal N, et al
    Unravelling the therapeutic potential of forkhead box proteins in breast cancer: An update (Review).
    Oncol Rep. 2024;52:92.
    PubMed         Abstract available
    
    
75. YANG X, Liang B, Zhang L, Zhang M, et al
    Ursolic acid inhibits the proliferation of triple?negative breast cancer stem?like cells through NRF2?mediated ferroptosis.
    Oncol Rep. 2024;52:94.
    PubMed         Abstract available
    
    

    
    Oncology

76. JEON C, Kang SH, Kim SB, Paik NS, et al
    Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.
    Oncology. 2024;102:465-475.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

77. XIE X, Sinha S
    Quantitative estimates of the regulatory influence of long non-coding RNAs on global gene expression variation using TCGA breast cancer transcriptomic data.
    PLoS Comput Biol. 2024;20:e1012103.
    PubMed         Abstract available
    
    

    
    PLoS Genet

78. GOMEZ ACUNA LI, Flyamer I, Boyle S, Friman ET, et al
    Transcription decouples estrogen-dependent changes in enhancer-promoter contact frequencies and spatial proximity.
    PLoS Genet. 2024;20:e1011277.
    PubMed         Abstract available
    
    

    
    PLoS One

79. KALSOOM A, Altaf A, Sattar H, Maqbool T, et al
    Gene expression and anticancer evaluation of Kigelia africana (Lam.) Benth. Extracts using MDA-MB-231 and MCF-7 cell lines.
    PLoS One. 2024;19:e0303134.
    PubMed         Abstract available
    
    
80. CONZ L, Jales RM, Doria MT, Melloni I, et al
    Predictive value of ultrasound doppler parameters in neoadjuvant chemotherapy response of breast cancer: Prospective comparison with magnetic resonance and mammography.
    PLoS One. 2024;19:e0302527.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

81. HUNT KN, Conners AL, Gray L, Hruska CB, et al
    Molecular Breast Imaging Biopsy with a Dual-Detector System.
    Radiol Imaging Cancer. 2024;6:e230186.
    PubMed         Abstract available
    
    

    
    Radiology

82. LAURITZEN AD, Lillholm M, Lynge E, Nielsen M, et al
    Early Indicators of the Impact of Using AI in Mammography Screening for Breast Cancer.
    Radiology. 2024;311:e232479.
    PubMed         Abstract available
    
    
83. LEE AY, Friedewald SM
    Clinical Implementation of AI in Screening Mammography: The Essential Role of Prospective Evaluation.
    Radiology. 2024;311:e241124.
    PubMed        
    
    

    
    Radiother Oncol

84. HOGSBJERG KW, Offersen BV
    Author's response to Letter-to-the-Editor from Chang JS. concerning: "Benefit of respiratory gating in the Danish Breast Cancer Group partial breast irradiation trial".
    Radiother Oncol. 2024;197:110351.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.